A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2

A. C. Ogilvie, J. W. Baars, A. J M Eerenberg, C. E. Hack, H. M. Pinedo, L. G. Thijs, J. Wagstaff

Research output: Contribution to journalArticle

Abstract

In a pilot study six patients received 4 days' treatment with interleukin 2 (IL-2) [cumulative dose (CD) 264 ± 26 × 106 IU m-2] and Cl esterase inhibitor (Cl-INH) (loading dose 2,000 U, followed by 500-1,000 U twice daily). Toxicity was compared with that in patients given 4 days' treatment with standard (CD 66 ± 12 × 106 IU m-2) or escalating-dose (CD 99 ± 8 × 106 IU m-2) IL-2. IL-2-induced hypotension was equivalent and complement activation was less after IL-2 + Cl-INH (C3a = 10.5 ± 3.2 nmol 1-1) than following standard (14.1 ± 8.4 nmol 1-1) or escalating-dose (18.3 ± 2.9 nmnol l-1) IL-2. This study demonstrates that C1-INH administration during IL-2 treatment is safe and warrants further study to evaluate its ability to ameliorate IL-2-induced toxicity.

Original languageEnglish (US)
Pages (from-to)596-598
Number of pages3
JournalBritish Journal of Cancer
Volume69
Issue number3
Publication statusPublished - Mar 1994
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ogilvie, A. C., Baars, J. W., Eerenberg, A. J. M., Hack, C. E., Pinedo, H. M., Thijs, L. G., & Wagstaff, J. (1994). A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2. British Journal of Cancer, 69(3), 596-598.